Protagonist Therapeutics, Inc. (PTGX) fair value analysis
Nasdaq · Updated 2026-10-19
PTGX price how computed
Valuation status
No fair-value estimate yetPTGX has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for PTGX yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $128.75
- Sector
- Healthcare
- 12-month range
- $73.98–$158.62
- Market cap
- $8.33B
- From 52-week high
- -18.8%
- Shares outstanding
- 64.7M
- Rank in Healthcare by quality score
- #88 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Protagonist Therapeutics, Inc. is a biopharmaceutical company that develops medications focused on gastrointestinal and immunology disorders. The company is based in the United States and operates in the healthcare sector.
PTGX currently ranks #88 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $8.33B
- P/E (trailing)
- 125x
- Revenue (TTM)
- $282M
- Net margin
- 29.4%
- EPS (TTM)
- $1.03
- Gross margin
- 100.0%
- Debt / equity
- 0.01
- Shares outstanding
- 64.7M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Stable
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 30 · neutral
- 50-day average
- $145.39
- 200-day average
- $113.77
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 8 quarters vs consensus
- 4 beat, 4 missed
- Quarter by quarter
- 2026-06 ▲ beat (+8.5%)
2026-03 ▲ beat (+107.7%)
2025-12 ▼ miss (-102.8%)
2025-09 ▲ beat (+3.1%)
2025-06 ▼ miss (-5.8%)
2025-03 ▼ miss (-272.7%)
2024-12 ▲ beat (+692.0%)
2024-09 ▼ miss (-1.9%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 13 buy · 0 hold · 0 sell (13 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $178
- Target vs last price
- +38.3%
What our data shows for PTGX
- Shares are trading in the middle of their 12-month price range of $73.98–$158.62.
- The 14-day relative strength index sits at a neutral 30.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- PTGX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the PTGX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is PTGX stock undervalued?
TickrTrends has no fair-value estimate for PTGX yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is PTGX's TickrTrends verdict?
PTGX is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does PTGX compare to other Healthcare stocks?
PTGX ranks #88 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is PTGX overbought or oversold?
PTGX's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does PTGX report earnings next?
PTGX's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does PTGX usually beat earnings estimates?
Over its last 8 reported quarters PTGX beat the consensus estimate 4 times and missed 4 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about PTGX?
Of 13 analysts covering PTGX, 13 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $178 (+38.3% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.